Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Acknowledgment of Support

This activity is supported by an educational grant from Amgen Inc.

Oncology Briefings™: Optimizing Care in Oncogene-Driven Advanced NSCLC

Release Date: August 31, 2021
Expiration Date: August 31, 2022

Activity Overview

This online activity is designed to provide a concise, focused overview of molecular testing and targeted agents for patients diagnosed with non–small cell lung cancer (NSCLC). The engaging, multimedia format of this program includes audio commentary from an expert thought leader that is integrated with text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward nurses interested in the management of patients with lung cancer. Other health care professionals interested in the management of patients with lung cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Identify testing strategies and key molecular alterations relevant to the care of patients with NSCLC
  • Evaluate safety and efficacy data for current and emerging targeted therapies in NSCLC
  • Apply strategies to mitigate the impact of treatment-related toxicities from novel agents in patents with NSCLC
  • Integrate nursing strategies into clinical scenarios to optimize care for patients with NSCLC whose tumors possess molecular alterations

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Beth Sandy, MSN, CRNP, OCN
Beth Sandy, MSN, CRNP, OCN
Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA

Disclosures: Speaker's Bureau: Amgen, AstraZeneca, Merck & Co, Takeda Pharmaceutical, Jazz Pharmaceuticals.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By